Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Nov 1;102(9):1715–1723. doi: 10.1172/JCI3784

CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs.

S Agrawal 1, J Marquet 1, M H Delfau-Larue 1, C Copie-Bergman 1, H Jouault 1, F Reyes 1, A Bensussan 1, J P Farcet 1
PMCID: PMC509119  PMID: 9802885

Abstract

There is a dogma in tumor immunology that tumor-infiltrating lymphocytes (TIL) are defective based on their lack of antitumoral efficacy in vivo and on impaired response to in vitro functional tests. However, TIL have been compared usually with peripheral blood T lymphocytes, raising doubts on the conclusions drawn. Therefore, we compared TIL from B cell non-Hodgkin's lymphomas (NHL) with T cells from nonmalignant secondary lymphoid organs. NHL-TIL were unresponsive to activation by immobilized anti-CD3 mAb, although bypassing T cell receptor (TCR)/CD3 signaling led to proliferation. The poor proliferative responses of NHL-TIL could not be explained by quantitative defects in TCRzeta expression. NHL-TIL underwent marked spontaneous apoptosis in vitro with loss of approximately 50% of cells after 24 h of culture. This was associated with downregulation of the antiapoptotic Bcl-xL and Bcl-2 proteins, whereas viable NHL-TIL maintained their expression. IL-2, anti-CD3/IL-2, and manipulation of the Fas/Fas-ligand death pathway had no effect on NHL-TIL survival. Apoptosis was not due to increased cell cycling, as NHL-TIL were quiescent, nonproliferating cells. T cells from inflammatory, nonmalignant tissues gave similar functional results to NHL-TIL, suggesting the existence of factors common to the microenvironment of these diverse pathologies. Thus, the quiescent, anergic phenotype of NHL-TIL cannot be attributed solely to tumor factors, but rather is a feature of T cells from chronic inflammatory lesions.

Full Text

The Full Text of this article is available as a PDF (220.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akbar A. N., Borthwick N. J., Wickremasinghe R. G., Panayoitidis P., Pilling D., Bofill M., Krajewski S., Reed J. C., Salmon M. Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur J Immunol. 1996 Feb;26(2):294–299. doi: 10.1002/eji.1830260204. [DOI] [PubMed] [Google Scholar]
  2. Akbar A. N., Borthwick N., Salmon M., Gombert W., Bofill M., Shamsadeen N., Pilling D., Pett S., Grundy J. E., Janossy G. The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections. The role of apoptosis in T cell memory. J Exp Med. 1993 Aug 1;178(2):427–438. doi: 10.1084/jem.178.2.427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Alexander J. P., Kudoh S., Melsop K. A., Hamilton T. A., Edinger M. G., Tubbs R. R., Sica D., Tuason L., Klein E., Bukowski R. M. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res. 1993 Mar 15;53(6):1380–1387. [PubMed] [Google Scholar]
  4. Behrens T. W., Mueller D. L. Bcl-x and the regulation of survival in the immune system. Immunol Res. 1997;16(2):149–160. doi: 10.1007/BF02786359. [DOI] [PubMed] [Google Scholar]
  5. Blair P. J., Riley J. L., Levine B. L., Lee K. P., Craighead N., Francomano T., Perfetto S. J., Gray G. S., Carreno B. M., June C. H. CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction. J Immunol. 1998 Jan 1;160(1):12–15. [PubMed] [Google Scholar]
  6. Boehme S. A., Lenardo M. J. Propriocidal apoptosis of mature T lymphocytes occurs at S phase of the cell cycle. Eur J Immunol. 1993 Jul;23(7):1552–1560. doi: 10.1002/eji.1830230724. [DOI] [PubMed] [Google Scholar]
  7. Boirivant M., Pica R., DeMaria R., Testi R., Pallone F., Strober W. Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis. J Clin Invest. 1996 Dec 1;98(11):2616–2622. doi: 10.1172/JCI119082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Boussiotis V. A., Freeman G. J., Gribben J. G., Daley J., Gray G., Nadler L. M. Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11059–11063. doi: 10.1073/pnas.90.23.11059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Boussiotis V. A., Lee B. J., Freeman G. J., Gribben J. G., Nadler L. M. Induction of T cell clonal anergy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas- and Bax-mediated programmed cell death. J Immunol. 1997 Oct 1;159(7):3156–3167. [PubMed] [Google Scholar]
  10. Broome H. E., Dargan C. M., Krajewski S., Reed J. C. Expression of Bcl-2, Bcl-x, and Bax after T cell activation and IL-2 withdrawal. J Immunol. 1995 Sep 1;155(5):2311–2317. [PubMed] [Google Scholar]
  11. Byrne J. A., Butler J. L., Cooper M. D. Differential activation requirements for virgin and memory T cells. J Immunol. 1988 Nov 15;141(10):3249–3257. [PubMed] [Google Scholar]
  12. Cardi G., Heaney J. A., Schned A. R., Phillips D. M., Branda M. T., Ernstoff M. S. T-cell receptor zeta-chain expression on tumor-infiltrating lymphocytes from renal cell carcinoma. Cancer Res. 1997 Aug 15;57(16):3517–3519. [PubMed] [Google Scholar]
  13. Cardoso A. A., Schultze J. L., Boussiotis V. A., Freeman G. J., Seamon M. J., Laszlo S., Billet A., Sallan S. E., Gribben J. G., Nadler L. M. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood. 1996 Jul 1;88(1):41–48. [PubMed] [Google Scholar]
  14. Chao D. T., Korsmeyer S. J. BCL-2 family: regulators of cell death. Annu Rev Immunol. 1998;16:395–419. doi: 10.1146/annurev.immunol.16.1.395. [DOI] [PubMed] [Google Scholar]
  15. Cho E. A., Riley M. P., Sillman A. L., Quill H. Altered protein tyrosine phosphorylation in anergic Th1 cells. J Immunol. 1993 Jul 1;151(1):20–28. [PubMed] [Google Scholar]
  16. Correa M. R., Ochoa A. C., Ghosh P., Mizoguchi H., Harvey L., Longo D. L. Sequential development of structural and functional alterations in T cells from tumor-bearing mice. J Immunol. 1997 Jun 1;158(11):5292–5296. [PubMed] [Google Scholar]
  17. Deckwerth T. L., Elliott J. L., Knudson C. M., Johnson E. M., Jr, Snider W. D., Korsmeyer S. J. BAX is required for neuronal death after trophic factor deprivation and during development. Neuron. 1996 Sep;17(3):401–411. doi: 10.1016/s0896-6273(00)80173-7. [DOI] [PubMed] [Google Scholar]
  18. Del Prete G., De Carli M., Almerigogna F., Giudizi M. G., Biagiotti R., Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol. 1993 Jan 15;150(2):353–360. [PubMed] [Google Scholar]
  19. Estaquier J., Tanaka M., Suda T., Nagata S., Golstein P., Ameisen J. C. Fas-mediated apoptosis of CD4+ and CD8+ T cells from human immunodeficiency virus-infected persons: differential in vitro preventive effect of cytokines and protease antagonists. Blood. 1996 Jun 15;87(12):4959–4966. [PubMed] [Google Scholar]
  20. Finke J. H., Zea A. H., Stanley J., Longo D. L., Mizoguchi H., Tubbs R. R., Wiltrout R. H., O'Shea J. J., Kudoh S., Klein E. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993 Dec 1;53(23):5613–5616. [PubMed] [Google Scholar]
  21. Franco J. L., Ghosh P., Wiltrout R. H., Carter C. R., Zea A. H., Momozaki N., Ochoa A. C., Longo D. L., Sayers T. J., Komschlies K. L. Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice. Cancer Res. 1995 Sep 1;55(17):3840–3846. [PubMed] [Google Scholar]
  22. Frisch S. M., Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994 Feb;124(4):619–626. doi: 10.1083/jcb.124.4.619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Gajewski T. F. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J Immunol. 1996 Jan 15;156(2):465–472. [PubMed] [Google Scholar]
  24. Gajewski T. F., Fallarino F., Uyttenhove C., Boon T. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J Immunol. 1996 Apr 15;156(8):2909–2917. [PubMed] [Google Scholar]
  25. Gribben J. G., Freeman G. J., Boussiotis V. A., Rennert P., Jellis C. L., Greenfield E., Barber M., Restivo V. A., Jr, Ke X., Gray G. S. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):811–815. doi: 10.1073/pnas.92.3.811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Groux H., Monte D., Plouvier B., Capron A., Ameisen J. C. CD3-mediated apoptosis of human medullary thymocytes and activated peripheral T cells: respective roles of interleukin-1, interleukin-2, interferon-gamma and accessory cells. Eur J Immunol. 1993 Jul;23(7):1623–1629. doi: 10.1002/eji.1830230734. [DOI] [PubMed] [Google Scholar]
  27. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J. E., Roncarolo M. G. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997 Oct 16;389(6652):737–742. doi: 10.1038/39614. [DOI] [PubMed] [Google Scholar]
  28. Guadagno T. M., Ohtsubo M., Roberts J. M., Assoian R. K. A link between cyclin A expression and adhesion-dependent cell cycle progression. Science. 1993 Dec 3;262(5139):1572–1575. doi: 10.1126/science.8248807. [DOI] [PubMed] [Google Scholar]
  29. Hargreaves R. G., Borthwick N. J., Gilardini Montani M. S., Piccolella E., Carmichael P., Lechler R. I., Akbar A. N., Lombardi G. Dissociation of T cell anergy from apoptosis by blockade of Fas/Apo-1 (CD95) signaling. J Immunol. 1997 Apr 1;158(7):3099–3107. [PubMed] [Google Scholar]
  30. Hathcock K. S., Laszlo G., Pucillo C., Linsley P., Hodes R. J. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med. 1994 Aug 1;180(2):631–640. doi: 10.1084/jem.180.2.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Hersh E. M., Drewinko B. Specific inhibition of lymphocyte blastogenic responses to mitogens by a factor produced by cultured human malignant lymphoma cells. Cancer Res. 1974 Jan;34(1):215–220. [PubMed] [Google Scholar]
  32. Horgan K. J., Van Seventer G. A., Shimizu Y., Shaw S. Hyporesponsiveness of "naive" (CD45RA+) human T cells to multiple receptor-mediated stimuli but augmentation of responses by co-stimuli. Eur J Immunol. 1990 May;20(5):1111–1118. doi: 10.1002/eji.1830200525. [DOI] [PubMed] [Google Scholar]
  33. Hsu S. M., Waldron J. W., Jr, Hsu P. L., Hough A. J., Jr Cytokines in malignant lymphomas: review and prospective evaluation. Hum Pathol. 1993 Oct;24(10):1040–1057. doi: 10.1016/0046-8177(93)90183-h. [DOI] [PubMed] [Google Scholar]
  34. Höllsberg P., Scholz C., Anderson D. E., Greenfield E. A., Kuchroo V. K., Freeman G. J., Hafler D. A. Expression of a hypoglycosylated form of CD86 (B7-2) on human T cells with altered binding properties to CD28 and CTLA-4. J Immunol. 1997 Nov 15;159(10):4799–4805. [PubMed] [Google Scholar]
  35. Jacob M. C., Piccinni M. P., Bonnefoix T., Sotto M. F., Couderc P., Bensa J. C., Sotto J. J. T lymphocytes from invaded lymph nodes in patients with B-cell-derived non-Hodgkin's lymphoma: reactivity toward the malignant clone. Blood. 1990 Mar 1;75(5):1154–1162. [PubMed] [Google Scholar]
  36. Kadin M. E., Agnarsson B. A., Ellingsworth L. R., Newcom S. R. Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease. Am J Pathol. 1990 Jun;136(6):1209–1214. [PMC free article] [PubMed] [Google Scholar]
  37. Koopman G., Reutelingsperger C. P., Kuijten G. A., Keehnen R. M., Pals S. T., van Oers M. H. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994 Sep 1;84(5):1415–1420. [PubMed] [Google Scholar]
  38. Krummel M. F., Allison J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995 Aug 1;182(2):459–465. doi: 10.1084/jem.182.2.459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Krummel M. F., Allison J. P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med. 1996 Jun 1;183(6):2533–2540. doi: 10.1084/jem.183.6.2533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Kudoh S., Wang Q., Hidalgo O. F., Rayman P., Tubbs R. R., Edinger M. G., Kolenko V., Panuto J., Bukowski R., Finke J. H. Responses to T cell receptor/CD3 and interleukin-2 receptor stimulation are altered in T cells from B cell non-Hodgkin's lymphomas. Cancer Immunol Immunother. 1995 Sep;41(3):175–184. doi: 10.1007/BF01521344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Levey D. L., Srivastava P. K. Alterations in T cells of cancer-bearers: whence specificity? Immunol Today. 1996 Aug;17(8):365–368. doi: 10.1016/0167-5699(96)10013-X. [DOI] [PubMed] [Google Scholar]
  42. Li X., Liu J., Park J. K., Hamilton T. A., Rayman P., Klein E., Edinger M., Tubbs R., Bukowski R., Finke J. T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report. Cancer Res. 1994 Oct 15;54(20):5424–5429. [PubMed] [Google Scholar]
  43. Loeffler C. M., Smyth M. J., Longo D. L., Kopp W. C., Harvey L. K., Tribble H. R., Tase J. E., Urba W. J., Leonard A. S., Young H. A. Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells. J Immunol. 1992 Aug 1;149(3):949–956. [PubMed] [Google Scholar]
  44. Maurice M. M., Lankester A. C., Bezemer A. C., Geertsma M. F., Tak P. P., Breedveld F. C., van Lier R. A., Verweij C. L. Defective TCR-mediated signaling in synovial T cells in rheumatoid arthritis. J Immunol. 1997 Sep 15;159(6):2973–2978. [PubMed] [Google Scholar]
  45. Miescher S., Stoeck M., Qiao L., Barras C., Barrelet L., von Fliedner V. Proliferative and cytolytic potentials of purified human tumor-infiltrating T lymphocytes. Impaired response to mitogen-driven stimulation despite T-cell receptor expression. Int J Cancer. 1988 Nov 15;42(5):659–666. doi: 10.1002/ijc.2910420504. [DOI] [PubMed] [Google Scholar]
  46. Miescher S., Whiteside T. L., Carrel S., von Fliedner V. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol. 1986 Mar 1;136(5):1899–1907. [PubMed] [Google Scholar]
  47. Miescher S., Whiteside T. L., Moretta L., von Fliedner V. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol. 1987 Jun 1;138(11):4004–4011. [PubMed] [Google Scholar]
  48. Migita K., Eguchi K., Kawabe Y., Tsukada T., Ichinose Y., Nagataki S., Ochi A. Defective TCR-mediated signaling in anergic T cells. J Immunol. 1995 Dec 1;155(11):5083–5087. [PubMed] [Google Scholar]
  49. Mizoguchi H., O'Shea J. J., Longo D. L., Loeffler C. M., McVicar D. W., Ochoa A. C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 1992 Dec 11;258(5089):1795–1798. doi: 10.1126/science.1465616. [DOI] [PubMed] [Google Scholar]
  50. Moore K. W., O'Garra A., de Waal Malefyt R., Vieira P., Mosmann T. R. Interleukin-10. Annu Rev Immunol. 1993;11:165–190. doi: 10.1146/annurev.iy.11.040193.001121. [DOI] [PubMed] [Google Scholar]
  51. Naito M., Nagashima K., Mashima T., Tsuruo T. Phosphatidylserine externalization is a downstream event of interleukin-1 beta-converting enzyme family protease activation during apoptosis. Blood. 1997 Mar 15;89(6):2060–2066. [PubMed] [Google Scholar]
  52. Nakagomi H., Petersson M., Magnusson I., Juhlin C., Matsuda M., Mellstedt H., Taupin J. L., Vivier E., Anderson P., Kiessling R. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 1993 Dec 1;53(23):5610–5612. [PubMed] [Google Scholar]
  53. Newcom S. R., Tagra K. K., Kadin M. E. Neutralizing antibodies against transforming growth factor beta potentiate the proliferation of Ki-1 positive lymphoma cells. Further evidence for negative autocrine regulation by transforming growth factor beta. Am J Pathol. 1992 Mar;140(3):709–718. [PMC free article] [PubMed] [Google Scholar]
  54. Nuñez G., London L., Hockenbery D., Alexander M., McKearn J. P., Korsmeyer S. J. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol. 1990 May 1;144(9):3602–3610. [PubMed] [Google Scholar]
  55. Perez V. L., Van Parijs L., Biuckians A., Zheng X. X., Strom T. B., Abbas A. K. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. 1997 Apr;6(4):411–417. doi: 10.1016/s1074-7613(00)80284-8. [DOI] [PubMed] [Google Scholar]
  56. Peuchmaur M., Emilie D., Crevon M. C., Brousse N., Gaulard P., D'Agay M. F., Galanaud P., Solal-Celigny P. Interleukin-2 and interferon-gamma production in follicular lymphomas. Am J Clin Pathol. 1991 Jan;95(1):55–62. doi: 10.1093/ajcp/95.1.55. [DOI] [PubMed] [Google Scholar]
  57. Pirzer U. C., Schürmann G., Post S., Betzler M., Meuer S. C. Differential responsiveness to CD3-Ti vs. CD2-dependent activation of human intestinal T lymphocytes. Eur J Immunol. 1990 Oct;20(10):2339–2342. doi: 10.1002/eji.1830201025. [DOI] [PubMed] [Google Scholar]
  58. Ranges G. E., Figari I. S., Espevik T., Palladino M. A., Jr Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med. 1987 Oct 1;166(4):991–998. doi: 10.1084/jem.166.4.991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Rieux-Laucat F., Le Deist F., Hivroz C., Roberts I. A., Debatin K. M., Fischer A., de Villartay J. P. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995 Jun 2;268(5215):1347–1349. doi: 10.1126/science.7539157. [DOI] [PubMed] [Google Scholar]
  60. Roszman T., Elliott L., Brooks W. Modulation of T-cell function by gliomas. Immunol Today. 1991 Oct;12(10):370–374. doi: 10.1016/0167-5699(91)90068-5. [DOI] [PubMed] [Google Scholar]
  61. Salmon M., Scheel-Toellner D., Huissoon A. P., Pilling D., Shamsadeen N., Hyde H., D'Angeac A. D., Bacon P. A., Emery P., Akbar A. N. Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest. 1997 Feb 1;99(3):439–446. doi: 10.1172/JCI119178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Schiavon V., Roth P., Bolton W. E., Farcet J. P., Bensussan A., Boumsell L. Lymphocytes subsets in normal individuals: analysis by four color immunofluorescence and flow cytometry on whole blood. Tissue Antigens. 1996 Oct;48(4 Pt 1):312–318. doi: 10.1111/j.1399-0039.1996.tb02650.x. [DOI] [PubMed] [Google Scholar]
  63. Tada T., Ohzeki S., Utsumi K., Takiuchi H., Muramatsu M., Li X. F., Shimizu J., Fujiwara H., Hamaoka T. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol. 1991 Feb 1;146(3):1077–1082. [PubMed] [Google Scholar]
  64. Taga K., Mostowski H., Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood. 1993 Jun 1;81(11):2964–2971. [PubMed] [Google Scholar]
  65. Toellner K. M., Scheel-Toellner D., Sprenger R., Duchrow M., Trümper L. H., Ernst M., Flad H. D., Gerdes J. The human germinal centre cells, follicular dendritic cells and germinal centre T cells produce B cell-stimulating cytokines. Cytokine. 1995 May;7(4):344–354. doi: 10.1006/cyto.1995.0044. [DOI] [PubMed] [Google Scholar]
  66. Voorzanger N., Touitou R., Garcia E., Delecluse H. J., Rousset F., Joab I., Favrot M. C., Blay J. Y. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res. 1996 Dec 1;56(23):5499–5505. [PubMed] [Google Scholar]
  67. Vánky F., Nagy N., Hising C., Sjövall K., Larson B., Klein E. Human ex vivo carcinoma cells produce transforming growth factor beta and thereby can inhibit lymphocyte functions in vitro. Cancer Immunol Immunother. 1997 Jan;43(6):317–323. doi: 10.1007/s002620050339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Wang Q., Stanley J., Kudoh S., Myles J., Kolenko V., Yi T., Tubbs R., Bukowski R., Finke J. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. J Immunol. 1995 Aug 1;155(3):1382–1392. [PubMed] [Google Scholar]
  69. Xerri L., Devilard E., Hassoun J., Olive D., Birg F. In vivo expression of the CTLA4 inhibitory receptor in malignant and reactive cells from human lymphomas. J Pathol. 1997 Oct;183(2):182–187. doi: 10.1002/(SICI)1096-9896(199710)183:2<182::AID-PATH918>3.0.CO;2-I. [DOI] [PubMed] [Google Scholar]
  70. Xerri L., Mathoulin M. P., Birg F., Bouabdallah R., Stoppa A. M., Hassoun J. Heterogeneity of rearranged T-cell receptor V-alpha and V-beta transcripts in tumor-infiltrating lymphocytes from Hodgkin's disease and non-Hodgkin's lymphoma. Am J Clin Pathol. 1994 Jan;101(1):76–80. doi: 10.1093/ajcp/101.1.76. [DOI] [PubMed] [Google Scholar]
  71. de Waal Malefyt R., Yssel H., de Vries J. E. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol. 1993 Jun 1;150(11):4754–4765. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES